


## Ulevostinag

Cat. No.:	HY-139586
CAS No.:	2082743-96-0
Molecular Formula:	C <sub>20</sub> H <sub>22</sub> F <sub>2</sub> N <sub>10</sub> O <sub>9</sub> P <sub>2</sub> S <sub>2</sub>
Molecular Weight:	710.52
Target:	STING
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Ulevostinag (MK-1454) is a potent cyclic dinucleotide agonist stimulator of interferon genes (STING). Ulevostinag (MK-1454) acts in the intra-tumoral route by targeting the stimulator of interferon genes (STING) protein. Ulevostinag (MK-1454) can be used for immuno-tumor cancer disease research <sup>[1]</sup> .																
<b>In Vivo</b>	<p>Ulevostinag (MK-1454) (5 µg, 20 µg for intratumorally) can activate tumor-specific immune responses in MC38 injected tumors and inhibit tumor growth at untreated, distal sites<sup>[1]</sup>.</p> <p>Ulevostinag (MK-1454) (4 µg for intratumorally on day 0, 3 and 7) results in complete tumor regression and enhances the efficacy of anti-PD1 therapy in MC38 and B16F10 tumor mice model<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>MC38 colon adenocarcinoma tumor-bearing mice<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>5 µg, 20 µg</td> </tr> <tr> <td>Administration:</td> <td>intratumorally</td> </tr> <tr> <td>Result:</td> <td>Regressed the injected (right) tumors and was detected in injected and noninjected tumors as well as plasma when dosed at 20 µg. Elevated IFN-β and proinflammatory cytokines IL-6 and TNF-α in injected tumors.</td> </tr> </table> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>MC38 and B16F10 tumor mice model<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>4 µg</td> </tr> <tr> <td>Administration:</td> <td>intratumorally</td> </tr> <tr> <td>Result:</td> <td>Improved tumor growth inhibition with 7 CRs out of 10 mice over 28 days.</td> </tr> </table>	Animal Model:	MC38 colon adenocarcinoma tumor-bearing mice <sup>[1]</sup>	Dosage:	5 µg, 20 µg	Administration:	intratumorally	Result:	Regressed the injected (right) tumors and was detected in injected and noninjected tumors as well as plasma when dosed at 20 µg. Elevated IFN-β and proinflammatory cytokines IL-6 and TNF-α in injected tumors.	Animal Model:	MC38 and B16F10 tumor mice model <sup>[1]</sup>	Dosage:	4 µg	Administration:	intratumorally	Result:	Improved tumor growth inhibition with 7 CRs out of 10 mice over 28 days.
Animal Model:	MC38 colon adenocarcinoma tumor-bearing mice <sup>[1]</sup>																
Dosage:	5 µg, 20 µg																
Administration:	intratumorally																
Result:	Regressed the injected (right) tumors and was detected in injected and noninjected tumors as well as plasma when dosed at 20 µg. Elevated IFN-β and proinflammatory cytokines IL-6 and TNF-α in injected tumors.																
Animal Model:	MC38 and B16F10 tumor mice model <sup>[1]</sup>																
Dosage:	4 µg																
Administration:	intratumorally																
Result:	Improved tumor growth inhibition with 7 CRs out of 10 mice over 28 days.																

### REFERENCES

[1]. Chang W, et al. Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer. *J Med Chem.* 2022 Apr 14;65(7):5675-5689.

---

[2]. Zawit M, et al. Current status of intralesional agents in treatment of malignant melanoma. *Ann Transl Med.* 2021 Jun;9(12):1038.

[3]. Gogoi H, et al. The Age of Cyclic Dinucleotide Vaccine Adjuvants. *Vaccines (Basel).* 2020 Aug 13;8(3):453.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA